More Company News

Avacta

Successful completion of fourth AVA6000 dose escalation
17 Jan 2023Read More

Avacta

Avacta to host Therapeutics Division Science Day
19 Dec 2022Read More

Avacta

Result of the Open Offer
08 Nov 2022Read More

Avacta

Avacta to present at Theranostics FAP summit
31 Oct 2022Read More

Avacta

Result of placing
18 Oct 2022Read More

Avacta

Proposed placing, open offer and issue of convertible bonds
18 Oct 2022Read More

Avacta

Proposed acquisition of Launch Diagnostics
18 Oct 2022Read More

Avacta

Interim H122 results
29 Sep 2022Read More

Avacta

US Orphan Drug designation for AVA6000
05 Sep 2022Read More

Avacta

AVA6000 Phase I moves to fourth cohort
01 Sep 2022Read More

1 2 3 4
Return to Avacta
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).